Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I first-in-human trial of modified-release formulations of methylphenidate (including HLD 200) versus immediate-release methylphenidate in adult volunteers

Trial Profile

Phase I first-in-human trial of modified-release formulations of methylphenidate (including HLD 200) versus immediate-release methylphenidate in adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 19 Apr 2017 According to an Ironshore Pharmaceutical and Development media release, clinical data will be presented at the 6th World Congress on ADHD (Attention Deficit / Hyperactivity Disorder) 2017.
    • 27 Jun 2013 New trial record
    • 25 Jun 2013 Positive results reported in a Highland Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top